LG 631

Drug Profile

LG 631

Alternative Names: LG631; LG631-CD34; Stem cell therapy - Case Western Reserve University/Opus Bio

Latest Information Update: 05 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Case Western Reserve University
  • Developer Case Western Reserve University; Opus Bio
  • Class Chemoprotectants; Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Gene transference; MGMT protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chemotherapy-induced damage
  • New Molecular Entity No

Highest Development Phases

  • Suspended Chemotherapy-induced damage

Most Recent Events

  • 20 Dec 2016 Suspended - Phase-I for Chemotherapy induced damage in USA (Parenteral) (NCT01269424)
  • 27 Jul 2015 Phase-I clinical trials in Chemotherapy induced damage in USA (Parenteral)
  • 14 Aug 2014 Lentigen Corporation starts operating as Opus Bio and gains certain rights to use lentiviral technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top